EP4569112A1 — Methods and compositions for modulating splicing at alternative splice sites
Assigned to Remix Therapeutics Inc · Expires 2025-06-18 · 1y expired
What this patent protects
The present disclosure features bifunctional oligonucleotides and related compositions that, inter alia , modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
USPTO Abstract
The present disclosure features bifunctional oligonucleotides and related compositions that, inter alia , modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.